Status:
COMPLETED
A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia
Lead Sponsor:
Kanisa Pharmaceuticals
Conditions:
Leukemia, Myeloid
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Chemotherapy drugs use different ways to stop cancer cells from dividing so they stop growing or die. Zosuquidar may help Gemtuzumab Ozogamicin (GO) kill more cancer cells by making cancer cells more ...
Detailed Description
Purpose: Phase I: Determine the optimal dose and schedule of GO and zosuquidar when used in combination. Phase II: Determine the complete remission rate (CR+CRp)
Eligibility Criteria
Inclusion
- Morphologic evidence of acute myeloid leukemia in first relapse.
- Phase I: 18 years or older, Phase II: 50 years or older
Exclusion
- Prior treatment with zosuquidar
- Any investigational agent within 1 month of enrollment and lack of recovery from toxicities secondary to those agents
- History of stem cell transplant
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2008
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT00233909
Start Date
October 1 2005
End Date
March 1 2008
Last Update
April 1 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.